These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 33612044)

  • 1. Plant-made vaccines against parasites: bioinspired perspectives to fight against Chagas disease.
    Ramos-Vega A; Monreal-Escalante E; Dumonteil E; Bañuelos-Hernández B; Angulo C
    Expert Rev Vaccines; 2021 Nov; 20(11):1373-1388. PubMed ID: 33612044
    [No Abstract]   [Full Text] [Related]  

  • 2. Gene-deleted live-attenuated Trypanosoma cruzi parasites as vaccines to protect against Chagas disease.
    Sánchez-Valdéz FJ; Pérez Brandán C; Ferreira A; Basombrío MÁ
    Expert Rev Vaccines; 2015 May; 14(5):681-97. PubMed ID: 25496192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trypanosoma cruzi 80 kDa prolyl oligopeptidase (Tc80) as a novel immunogen for Chagas disease vaccine.
    Bivona AE; Sánchez Alberti A; Matos MN; Cerny N; Cardoso AC; Morales C; González G; Cazorla SI; Malchiodi EL
    PLoS Negl Trop Dis; 2018 Mar; 12(3):e0006384. PubMed ID: 29601585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Knockout of the dhfr-ts gene in Trypanosoma cruzi generates attenuated parasites able to confer protection against a virulent challenge.
    Perez Brandan C; Padilla AM; Xu D; Tarleton RL; Basombrio MA
    PLoS Negl Trop Dis; 2011 Dec; 5(12):e1418. PubMed ID: 22180798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of a recombinant vaccine against Trypanosoma cruzi in Rhesus macaques.
    Dumonteil E; Herrera C; Tu W; Goff K; Fahlberg M; Haupt E; Kaur A; Marx PA; Ortega-Lopez J; Hotez PJ; Bottazzi ME
    Vaccine; 2020 Jun; 38(29):4584-4591. PubMed ID: 32417142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cruzipain and Its Physiological Inhibitor, Chagasin, as a DNA-Based Therapeutic Vaccine Against
    Cerny N; Bivona AE; Sanchez Alberti A; Trinitario SN; Morales C; Cardoso Landaburu A; Cazorla SI; Malchiodi EL
    Front Immunol; 2020; 11():565142. PubMed ID: 33162979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chagas disease vaccine design: the search for an efficient Trypanosoma cruzi immune-mediated control.
    Bivona AE; Alberti AS; Cerny N; Trinitario SN; Malchiodi EL
    Biochim Biophys Acta Mol Basis Dis; 2020 May; 1866(5):165658. PubMed ID: 31904415
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    da Costa KM; Marques da Fonseca L; Dos Reis JS; Santos MARDC; Previato JO; Mendonça-Previato L; Freire-de-Lima L
    Front Cell Infect Microbiol; 2021; 11():768450. PubMed ID: 34765570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experimental Vaccines against Chagas Disease: A Journey through History.
    Rodríguez-Morales O; Monteón-Padilla V; Carrillo-Sánchez SC; Rios-Castro M; Martínez-Cruz M; Carabarin-Lima A; Arce-Fonseca M
    J Immunol Res; 2015; 2015():489758. PubMed ID: 26090490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterologous Chimeric Construct Comprising a Modified Bacterial Superantigen and a Cruzipain Domain Confers Protection Against
    Antonoglou MB; Sánchez Alberti A; Redolfi DM; Bivona AE; Fernández Lynch MJ; Noli Truant S; Sarratea MB; Iannantuono López LV; Malchiodi EL; Fernández MM
    Front Immunol; 2020; 11():1279. PubMed ID: 32695105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maternal infection with Trypanosoma cruzi and congenital Chagas disease induce a trend to a type 1 polarization of infant immune responses to vaccines.
    Dauby N; Alonso-Vega C; Suarez E; Flores A; Hermann E; Córdova M; Tellez T; Torrico F; Truyens C; Carlier Y
    PLoS Negl Trop Dis; 2009 Dec; 3(12):e571. PubMed ID: 20041029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in Drug Discovery against Neglected Tropical Diseases: Human African and American Trypanosomiasis.
    Peerzada MN; Gaur A; Azam A
    Curr Med Chem; 2021; 28(36):7544-7582. PubMed ID: 33949927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression, purification, immunogenicity, and protective efficacy of a recombinant Tc24 antigen as a vaccine against Trypanosoma cruzi infection in mice.
    Martinez-Campos V; Martinez-Vega P; Ramirez-Sierra MJ; Rosado-Vallado M; Seid CA; Hudspeth EM; Wei J; Liu Z; Kwityn C; Hammond M; Ortega-López J; Zhan B; Hotez PJ; Bottazzi ME; Dumonteil E
    Vaccine; 2015 Aug; 33(36):4505-12. PubMed ID: 26192358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccine development against Trypanosoma cruzi and Chagas disease.
    Vázquez-Chagoyán JC; Gupta S; Garg NJ
    Adv Parasitol; 2011; 75():121-46. PubMed ID: 21820554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetically attenuated Trypanosoma cruzi parasites as a potential vaccination tool.
    Pérez Brandan C; Basombrío MÁ
    Bioengineered; 2012; 3(4):242-6. PubMed ID: 22705838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antigenicity and diagnostic potential of vaccine candidates in human Chagas disease.
    Gupta S; Wan X; Zago MP; Sellers VC; Silva TS; Assiah D; Dhiman M; Nuñez S; Petersen JR; Vázquez-Chagoyán JC; Estrada-Franco JG; Garg NJ
    PLoS Negl Trop Dis; 2013; 7(1):e2018. PubMed ID: 23350012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Between a bug and a hard place: Trypanosoma cruzi genetic diversity and the clinical outcomes of Chagas disease.
    Messenger LA; Miles MA; Bern C
    Expert Rev Anti Infect Ther; 2015 Aug; 13(8):995-1029. PubMed ID: 26162928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant Mycobacterium bovis BCG is a promising platform to develop vaccines against Trypansoma cruzi infection.
    Bontempi I; Leal K; Prochetto E; Díaz G; Cabrera G; Bortolotti A; Morbidoni HR; Borsuk S; Dellagostin O; Marcipar I
    Clin Exp Immunol; 2020 Sep; 201(3):306-316. PubMed ID: 32464684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neglected tropical diseases, bioinformatics, and vaccines.
    Rodrigues MM; Ersching J
    J Infect Dis; 2015 Jan; 211(2):175-7. PubMed ID: 25070940
    [No Abstract]   [Full Text] [Related]  

  • 20. Drug-cured experimental Trypanosoma cruzi infections confer long-lasting and cross-strain protection.
    Mann GS; Francisco AF; Jayawardhana S; Taylor MC; Lewis MD; Olmo F; de Freitas EO; Leoratti FMS; López-Camacho C; Reyes-Sandoval A; Kelly JM
    PLoS Negl Trop Dis; 2020 Apr; 14(4):e0007717. PubMed ID: 32302312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.